WO2005020879A3 - Compositions for treating pathologies that necessitate suppression of gastric acid secretion - Google Patents

Compositions for treating pathologies that necessitate suppression of gastric acid secretion Download PDF

Info

Publication number
WO2005020879A3
WO2005020879A3 PCT/IB2004/002745 IB2004002745W WO2005020879A3 WO 2005020879 A3 WO2005020879 A3 WO 2005020879A3 IB 2004002745 W IB2004002745 W IB 2004002745W WO 2005020879 A3 WO2005020879 A3 WO 2005020879A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
gastric
acid secretion
necessitate
suppression
Prior art date
Application number
PCT/IB2004/002745
Other languages
French (fr)
Other versions
WO2005020879A2 (en
Inventor
Ayelet David
Sabina Glozman
Lada Paul
Original Assignee
Vecta Ltd
Ayelet David
Sabina Glozman
Lada Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vecta Ltd, Ayelet David, Sabina Glozman, Lada Paul filed Critical Vecta Ltd
Priority to EP04769171A priority Critical patent/EP1658089A4/en
Priority to CA002536906A priority patent/CA2536906A1/en
Priority to JP2006524456A priority patent/JP2007503427A/en
Priority to AU2004268446A priority patent/AU2004268446A1/en
Publication of WO2005020879A2 publication Critical patent/WO2005020879A2/en
Publication of WO2005020879A3 publication Critical patent/WO2005020879A3/en
Priority to US11/351,001 priority patent/US20060135406A1/en
Priority to IL173944A priority patent/IL173944A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further comprises at least one agent that preserves the availability of PG in the gastric fluids, thus enabling PG to act locally in the stomach. Unexpectedly, the compositions of the present invention exhibit anti-acid activity locally in the stomach that is meal-independent, exhibit fast onset and prolonged inhibition of acid secretion.
PCT/IB2004/002745 2002-10-14 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion WO2005020879A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04769171A EP1658089A4 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
CA002536906A CA2536906A1 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
JP2006524456A JP2007503427A (en) 2003-08-27 2004-08-25 Composition for treating medical conditions requiring suppression of gastric acid secretion
AU2004268446A AU2004268446A1 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US11/351,001 US20060135406A1 (en) 2002-10-14 2006-02-09 Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
IL173944A IL173944A0 (en) 2003-08-27 2006-02-26 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49793003P 2003-08-27 2003-08-27
US60/497,930 2003-08-27
US54431804P 2004-02-17 2004-02-17
US60/544,318 2004-02-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/351,001 Continuation-In-Part US20060135406A1 (en) 2002-10-14 2006-02-09 Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion

Publications (2)

Publication Number Publication Date
WO2005020879A2 WO2005020879A2 (en) 2005-03-10
WO2005020879A3 true WO2005020879A3 (en) 2005-05-19

Family

ID=34278571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002745 WO2005020879A2 (en) 2002-10-14 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Country Status (8)

Country Link
EP (1) EP1658089A4 (en)
JP (1) JP2007503427A (en)
KR (1) KR20060083198A (en)
AU (1) AU2004268446A1 (en)
CA (1) CA2536906A1 (en)
IL (1) IL173944A0 (en)
RU (1) RU2006109357A (en)
WO (1) WO2005020879A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506730A (en) * 2003-09-24 2007-03-22 ベクタ・リミテッド Oral composition for stimulating gastric acid secretion containing pentagastrin
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CN101389316A (en) * 2005-12-28 2009-03-18 武田药品工业株式会社 Controlled release solid preparation
BRPI0620788A2 (en) * 2005-12-28 2011-11-22 Takeda Pharmaceutical solid preparation
PL2046334T3 (en) 2006-07-25 2015-02-27 Vecta Ltd Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP4311542A1 (en) * 2022-07-27 2024-01-31 Roquette Freres Floating tab-in-tab dosage forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US20010022985A1 (en) * 1998-11-17 2001-09-20 Moeller Patrick W. Method for covering a food product with collagen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
JP3181062B2 (en) * 1991-01-31 2001-07-03 帝國製薬株式会社 Lower digestive tract disintegrating oral preparation
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US20010022985A1 (en) * 1998-11-17 2001-09-20 Moeller Patrick W. Method for covering a food product with collagen

Also Published As

Publication number Publication date
IL173944A0 (en) 2006-07-05
EP1658089A4 (en) 2007-03-14
EP1658089A2 (en) 2006-05-24
KR20060083198A (en) 2006-07-20
AU2004268446A1 (en) 2005-03-10
CA2536906A1 (en) 2005-03-10
WO2005020879A2 (en) 2005-03-10
JP2007503427A (en) 2007-02-22
RU2006109357A (en) 2007-10-10

Similar Documents

Publication Publication Date Title
TW200714278A (en) Compositions and methods for inhibiting gastric acid secretion
EP1661574A4 (en) Beta-hydroxy short to medium chain fatty acid polymer
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA05013048A (en) Stabilized pharmaceutical peptide compositions.
PL1992361T3 (en) Remedy or preventive for digestive ulcer
MY121032A (en) Heterocyclic compounds for inhibition of gastric acid secretion, processes for their preparation and pharmaceutical compositions thereof
WO2006116731A3 (en) Personal care compositions comprising a dipeptide
WO2006011050A3 (en) Pyridine derivatives
WO2005020879A3 (en) Compositions for treating pathologies that necessitate suppression of gastric acid secretion
IS7545A (en) 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use in renin-inhibiting treatment of hypertension, cardiovascular or renal disease
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
TW200514772A (en) Novel tetrahydropyridine derivatives
WO2000011000A3 (en) New compounds
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2000010999A3 (en) New compounds
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2009138884A3 (en) Compositions and methods for inhibiting gastric acid secretion
WO2002043666A3 (en) Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function
WO2003075842A3 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024634.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004769171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004268446

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11351001

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004268446

Country of ref document: AU

Date of ref document: 20040825

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004268446

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2536906

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067003852

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 173944

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006524456

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1617/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006109357

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004769171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11351001

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067003852

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2004769171

Country of ref document: EP